Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Son Espases University Hospital

5 abstracts

Abstract
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.
Org: Medical Oncology Department, Institute of Biomedicine of Seville, Hospital Universitario y Politécnico La Fe, Son Espases University Hospital, University Hospital Virgen del Rocio,
Abstract
ImmunoSarc II master trial (phase II of sunitinib and nivolumab): Results from the dedifferentiated chondrosarcoma (DDCS) cohort—A GEIS, ISG and UCL study.
Org: University College London Hospital NHS Trust and Great Ormond Street Hospital, Health Research Institute-Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid (IIS-FJD, UAM), IRCCS Istituto Ortopedico Rizzoli, Hospital Universitario Miguel Servet,
Abstract
SELISARC: A Spanish Sarcoma Group (GEIS) phase I/II trial of selinexor plus gemcitabine in selected sarcoma subtypes—Results of the phase I part.
Org: Fundacion Jimenez Diaz University Hospital, Hospital Clinico San Carlos, Health Research Institute-Fundación Jiménez Díaz University Hospital, Hospital Universitario La Paz - CIBERONC, Hospital U. Miguel Servet,
Abstract
SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.
Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Central University Hospital of Asturias, Hospital Juan Ramón Jiménez de Huelva, Hospital Clínic de Barcelona, IDIBAPS,
Abstract
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.
Org: Hospital Universitario Puerta de Hierro-Majadahonda, Hospital Universitario A Coruña, Son Espases University Hospital, Hospital Regional Carlos Haya, Catalan Institute of Oncology-Hospitalet,